Ads
related to: Tardive Dyskinesia Treatment
Search results
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
Investor's Business Daily· 1 day agoAnd, with a bevy of good news this year, the biotech stock is angling for a record high. The company...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoAll of these will be key to helping bolster Neurocrine's sales. The company is well known for...
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Investor's Business Daily· 7 days agoThe flat base forged next to a prior flat base. Aggressive investors could use Wednesday's high of...
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
Yucaipa News Mirror· 3 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las ...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of...
NBC 17 Raleigh· 1 day agoNBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered ...
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact...
WRBL Columbus· 1 day agoThe CAHtalyst Adult study baseline data demonstrate the potential long-term consequences of current CAH treatments, with many patients in young adulthood experiencing disorders ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoNxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, ...
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program...
WDTN-TV 2 Dayton· 3 days agoNeurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst ...
Ads
related to: Tardive Dyskinesia Treatment
